Regenics Strengthens Its Leadership with Brynjólfur Gísli Eyjólfsson as Chair

In a significant move, Regenics AS, a leading Norwegian biotech firm specializing in marine-based wound care solutions, has appointed Brynjólfur Gísli Eyjólfsson as the Chair of its Board of Directors. This change was officially announced following a General Meeting held on June 16, 2025, where Mr. Eyjólfsson's appointment garnered unanimous approval.

Mr. Eyjólfur Gísli Eyjólfsson brings a wealth of experience to his new role, particularly from the blue economy and investment sectors. Most notably, he currently serves as the Fund Manager for the IS Haf Fund, the largest investor in Nordic Blue ehf. Notably, Nordic Blue holds a 38.1% stake in Regenics, courtesy of its participation in two significant financing rounds recently. With such credentials and experience, Eyjólfsson is poised to provide pivotal leadership as Regenics approaches critical phases in its product development.

The newly constituted board includes experts Runhild Gammelsæter, Harald Nordal, Tore H. Rasmussen, and Beat Moser. Collectively, they contribute decades of expertise across various fields, including medical technology, regulation, commercialization, and clinical research. Their backgrounds span multiple successful ventures in healthcare, reflecting a deep-seated commitment to advancing medical solutions through innovative technology.

Upon accepting his new responsibilities, Mr. Eyjólfsson stated, "It is an honor to take on the role of Chair at Regenics. We believe the company's marine-based platform and its lead product Collex® have strong clinical and commercial potential. Nordic Blue and Haf Investments are committed to supporting the company as it moves into clinical development." He emphasized the board's dedication to nurturing the company's growth trajectory, especially as it navigates the complexities of transitioning from research to clinical application.

Regenics is notable for its development of next-generation wound care products, leveraging marine bioactives sourced from the pristine Norwegian coastline. At the forefront of its product line is Collex®, an advanced hydrogel dressing designed specifically for treating partial-thickness burns and chronic wounds. The proprietary HTX™ technology, derived from salmon roe, forms the cornerstone of this innovative product, which is currently undergoing preclinical trials.

The appointment of Mr. Eyjólfsson comes at a pivotal moment for Regenics, which is looking to capitalize on the burgeoning market for advanced wound care solutions. The board is set to combine practical industry insights with innovative research strategies, aimed at translating their vision into tangible healthcare solutions. By marrying marine biotechnology with practical applications, Regenics is spearheading a new wave of medical innovation.

In the wake of this leadership transition, Regenics extends its gratitude to the outgoing board chair, Jan A. Alfheim, acknowledging his dedication and efforts over the past four years. Under Alfheim's guidance, the company has navigated through foundational phases, positioning it for future success.

As Regenics embarks on this new chapter, the industry is watching closely. The integration of Mr. Eyjólfsson's experience and the collective strengths of the board presents a compelling proposition for stakeholders invested in the future of biotechnological advancements in healthcare. With targeted investments and a focus on product development, Regenics is on track to redefine the standards of wound care, leveraging natural resources to foster healing in an efficient and sustainable manner.

Regenics stands at the intersection of innovation, sustainability, and healthcare, promising a brighter future for wound management through its unique biotechnological contributions derived from marine ecosystems.